冻存的人脐带血CD34+细胞

冻存的人原代细胞

产品号 #(选择产品)

产品号 #70008_C

冻存的人原代细胞

Save on high-quality cells! Take advantage of our bulk pricing discounts and price matching offer to get the best value for your purchase.

HLA information from single donor CB CD34+ products can be provided upon request for specific lots. Please reach out to your sales representative or contact us directly for more information.

总览

选择即用型、符合伦理的人CD34+干细胞和祖细胞助您轻松开启实验。我们提供个性化的服务、定制产品、灵活的交付周期,并支持提前测试筛选并预留整个批次,以确保您获得所需的细胞。

通过免疫磁珠正选从脐带血中分离细胞,遵循机构审查委员会(IRB)批准的知情同意书和方案进行收集,并冻存于不含动物成分的CryoStor® CS10冻存液(产品号#07930)中。如有需要,可提供其他文档、高分辨率HLA分型(I类和II类等位基因)以及CMV状态。采集过程中添加檬酸盐-磷酸盐-葡萄糖(CPD)作为抗凝剂。选择产品选项后,供体信息(如BMI范围、年龄、种族等)可以在上面的评论框中查询。所有供体均经过HIV-1/2、乙肝和丙肝筛查。

CD34+干细胞和祖细胞可以与许多产品结合使用,包括StemSpan™MethoCult™MegaCult™MyeloCult™,以扩增和分化其他稀有细胞类型。

某些产品仅在特定地区出售。请与您当地的销售代表或产品与科学支持联系techsupport@stemcell.com获取更多信息。

欲了解更多信息,请浏览有关原代细胞的常见问题解答(FAQs)

包含
• Serum-free cryopreservation medium • 10% dimethyl sulfoxide (DMSO)
 
亚型
冻存
 
细胞类型
造血干/祖细胞
 
种属

 
细胞和组织来源
Cord Blood
 
供体状态
Normal
 
纯度
流式细胞术检测:CD34+ (占 CD45+ 细胞的百分比)≥ 90%
 

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
70008.3, 200-0001, 70008.4, 70008.1, 70008.5, 200-0002, 200-0000, 70008.2
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (7)

Publications (16)

Efficacy and safety of a clinically relevant foamy vector design in human hematopoietic repopulating cells. E. M. Everson et al. The journal of gene medicine 2018 JUL

Abstract

BACKGROUND Previous studies have shown that foamy viral (FV) vectors are a promising alternative to gammaretroviral and lentiviral vectors and also that insulators can improve FV vector safety. However, in a previous analysis of insulator effects on FV vector safety, strong viral promoters were used to elicit genotoxic events. In the present study, we developed and analyzed the efficacy and safety of a high-titer, clinically relevant FV vector driven by the housekeeping promoter elongation factor-1alpha$ and insulated with an enhancer blocking A1 insulator (FV-EGW-A1). METHODS Human CD34+ cord blood cells were exposed to an enhanced green fluorescent protein expressing vector, FV-EGW-A1, at a multiplicity of infection of 10 and then maintained in vitro or transplanted into immunodeficient mice. Flow cytometry was used to measure engraftment and marking in vivo. FV vector integration sites were analyzed to assess safety. RESULTS FV-EGW-A1 resulted in high-marking, multilineage engraftment of human repopulating cells with no evidence of silencing. Engraftment was highly polyclonal with no clonal dominance and a promising safety profile based on integration site analysis. CONCLUSIONS An FV vector with an elongation factor-1alpha$ promoter and an A1 insulator is a promising vector design for use in the clinic.
DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. D. C. Johnson et al. Nature medicine 2018 AUG

Abstract

Small-molecule inhibitors of the serine dipeptidases DPP8 and DPP9 (DPP8/9) induce a lytic form of cell death called pyroptosis in mouse and human monocytes and macrophages1,2. In mouse myeloid cells, Dpp8/9 inhibition activates the inflammasome sensor Nlrp1b, which in turn activates pro-caspase-1 to mediate cell death3, but the mechanism of DPP8/9 inhibitor-induced pyroptosis in human myeloid cells is not yet known. Here we show that the CARD-containing protein CARD8 mediates DPP8/9 inhibitor-induced pro-caspase-1-dependent pyroptosis in human myeloid cells. We further show that DPP8/9 inhibitors induce pyroptosis in the majority of human acute myeloid leukemia (AML) cell lines and primary AML samples, but not in cells from many other lineages, and that these inhibitors inhibit human AML progression in mouse models. Overall, this work identifies an activator of CARD8 in human cells and indicates that its activation by small-molecule DPP8/9 inhibitors represents a new potential therapeutic strategy for AML.
A neutralizing anti-G-CSFR antibody blocks G-CSF-induced neutrophilia without inducing neutropenia in nonhuman primates. Scalzo-Inguanti K et al. Journal of leukocyte biology 2017 MAY

Abstract

Neutrophils are the most abundant WBCs and have an essential role in the clearance of pathogens. Tight regulation of neutrophil numbers and their recruitment to sites of inflammation is critical in maintaining a balanced immune response. In various inflammatory conditions, such as rheumatoid arthritis, vasculitis, cystic fibrosis, and inflammatory bowel disease, increased serum G-CSF correlates with neutrophilia and enhanced neutrophil infiltration into inflamed tissues. We describe a fully human therapeutic anti-G-CSFR antibody (CSL324) that is safe and well tolerated when administered via i.v. infusion to cynomolgus macaques. CSL324 was effective in controlling G-CSF-mediated neutrophilia when administered either before or after G-CSF. A single ascending-dose study showed CSL324 did not alter steady-state neutrophil numbers, even at doses sufficient to completely prevent G-CSF-mediated neutrophilia. Weekly infusions of CSL324 (%10 mg/kg) for 3 wk completely neutralized G-CSF-mediated pSTAT3 phosphorylation without neutropenia. Moreover, repeat dosing up to 100 mg/kg for 12 wk did not result in neutropenia at any point, including the 12-wk follow-up after the last infusion. In addition, CSL324 had no observable effect on basic neutrophil functions, such as phagocytosis and oxidative burst. These data suggest that targeting G-CSFR may provide a safe and effective means of controlling G-CSF-mediated neutrophilia as observed in various inflammatory diseases.

更多信息

更多信息
Species Human
Contains • Serum-free cryopreservation medium • 10% dimethyl sulfoxide (DMSO)
Purity ≥ 90% CD34+ (as a percentage of CD45+ cells) by flow cytometry
Cell And Tissue Source Cord Blood
Donor Status Normal
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。